Last reviewed · How we verify
pALG/ rATG
pALG and rATG are immunosuppressive drugs that work by inhibiting T-cell activation and proliferation.
pALG and rATG are immunosuppressive drugs that work by inhibiting T-cell activation and proliferation. Used for Prevention of organ rejection in kidney transplant patients, Prevention of organ rejection in heart transplant patients.
At a glance
| Generic name | pALG/ rATG |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Drug class | Monoclonal antibody |
| Target | CD25 (IL-2 receptor alpha subunit) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
pALG (basiliximab) and rATG (thymoglobulin) are monoclonal antibodies that bind to and deplete T-cells, thereby reducing the immune response and preventing organ rejection in transplant patients.
Approved indications
- Prevention of organ rejection in kidney transplant patients
- Prevention of organ rejection in heart transplant patients
Common side effects
- Thrombocytopenia
- Leukopenia
- Anemia
- Neutropenia
Key clinical trials
- A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia (PHASE3)
- Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pALG/ rATG CI brief — competitive landscape report
- pALG/ rATG updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI